XML 83 R72.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT INFORMATION - Schedule of reconciliation to the consolidated net loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue:                
Screening revenue $ 36,194     $ 28,652     $ 103,575 $ 87,343
Costs and operating expenses:                
Stock-based compensation 14,139     17,449     44,518 72,502
Goodwill and intangible assets impairment 0     0     28,000 1,420,936
Total costs and operating expenses 161,485     212,159     541,327 2,139,563
Loss from operations (125,291)     (183,507)     (437,752) (2,052,220)
Other income (expense):                
Interest income 6,107     11,661     20,695 17,367
Other income (expense), net 466     (561)     (929) (514)
Benefit from income taxes 29,741     46,719     108,811 105,428
Net loss (88,977) $ (113,985) $ (106,213) (125,688) $ (1,585,337) $ (218,914) (309,175) (1,929,939)
Depreciation             13,686 14,865
Reportable Segment                
Revenue:                
Screening revenue 36,194     28,652     103,575 87,343
Costs and operating expenses:                
Compensation 53,375     84,733     173,537 257,578
Depreciation and intangible assets amortization expense 37,646     38,630     112,577 114,808
Stock-based compensation 13,868     16,871     43,068 70,980
Professional services 8,831     11,298     27,353 52,459
Cloud computing and information technology 6,416     7,517     19,537 23,619
Clinical studies 7,835     8,048     20,020 39,280
Laboratory supplies and research collaborations 3,242     8,556     10,421 37,631
Facilities 5,517     6,185     16,510 21,344
Other segment expenses 8,301     12,909     35,709 51,948
Goodwill and intangible assets impairment 0     0     28,000 1,420,936
Total costs and operating expenses 161,485     212,159     541,327 2,139,563
Loss from operations (125,291)     (183,507)     (437,752) (2,052,220)
Other income (expense):                
Interest income 6,107     11,661     20,695 17,367
Other income (expense), net 466     (561)     (929) (514)
Benefit from income taxes 29,741     46,719     108,811 105,428
Net loss (88,977)     (125,688)     (309,175) (1,929,939)
Depreciation 1,300     600     4,900 3,800
Screening revenue                
Revenue:                
Screening revenue [1] 32,807     25,374     96,319 77,076
Costs and operating expenses:                
Cost of revenue [2] 15,910     15,970     52,379 45,481
Screening revenue | Reportable Segment                
Revenue:                
Screening revenue 32,807     25,374     96,319 77,076
Costs and operating expenses:                
Cost of revenue 15,910     15,970     52,379 45,481
Development services revenue                
Revenue:                
Screening revenue 3,387     3,278     7,256 10,267
Costs and operating expenses:                
Cost of revenue [3] 544     1,442     2,216 3,499
Development services revenue | Reportable Segment                
Revenue:                
Screening revenue 3,387     3,278     7,256 10,267
Costs and operating expenses:                
Cost of revenue $ 544     $ 1,442     $ 2,216 $ 3,499
[1] ncludes related party screening revenue of $50 and $179 for the three and nine months ended September 30, 2025 and $129 and $366 for the three and nine months ended September 30, 2024, respectively.
[2] ncludes related party cost of screening revenue of $1,237 and $3,924 for the three and nine months ended September 30, 2025 and $3,658 and $9,784 for the three and nine months ended September 30, 2024, respectively.
[3] Includes related party cost of development services revenue of $78 and $260 for the three and nine months ended September 30, 2025 and $143 and $259 for the three and nine months ended September 30, 2024, respectively.